InflaRx (IFRX) Q2 2026 earnings summary

Executive summary

• Advanced izicopan development in ANCA-associated vasculitis (AAV) and select renal diseases, with Phase 2 planning ongoing and feasibility assessment for broader AAV strategy in Europe.

• Reported new pre-clinical data supporting izicopan's safety and differentiation as a next-generation oral C5aR inhibitor.

• Announced a €158.4 million cash position as of June 30, 2026, bolstered by a €119.3 million public offering in May, expected to fund operations and clinical development through 2029.

• Scheduled a Capital Markets Day for October 8, 2026, to provide updates on development strategy and clinical milestones.

Financial highlights

• Net loss for the six months ended June 30, 2026, was €16.2 million (€0.17 per share), improved from €22.7 million (€0.35 per share) year-over-year.

• Sales and marketing expenses dropped by €2.3 million to €0.1 million due to discontinued sales activities.

• Research and development expenses decreased by €5.3 million to €8.9 million, mainly from lower third-party and personnel costs.

• General and administrative expenses fell by €2.6 million to €5.7 million, reflecting reduced personnel and legal costs.

• Net financial result shifted to a €2.0 million loss from a €3.2 million gain, mainly due to fair value remeasurement of pre-funded warrants.

Outlook and guidance

• Sufficient cash runway projected through 2029, supporting multiple clinical milestones, including initiation and data readouts for izicopan in AAV and renal diseases.

• PK bridging study for izicopan in China expected to start late 2026 to accelerate proof-of-concept studies in additional inflammation and immunology indications.

• Engaging with EMA regarding regulatory pathways for vilobelimab and izicopan in Europe following changes in the competitive landscape.